脂肪原/TG003/AG-CR1-3656-M025/25毫克
商品编号：
AG-CR1-3656-M025
品牌：
Adipogen Inc
市场价：
¥5600.00
美元价：
3360.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | (Z)-1-(3-Ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one |
| Product Type | Chemical |
| Properties | |
| Formula | C13H15NO2S |
| MW | 249.3 |
| CAS | 300801-52-9 |
| Purity Chemicals | ≥98% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO (20mg/ml), ethanol (15mg/ml) or DMF (15mg/ml). |
| Identity | Determined by 1H-NMR. |
| InChi Key | BGVLELSCIHASRV-QPEQYQDCSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Keep under inert gas. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Potent, specific, reversible and ATP-competitive cell permeable inhibitor of Cdc2-like kinase (Clk) (IC50=15nM, 20nM, 200nM and >10µM for mClk4, mClk1, mClk2 and mClk3, respectively). Cdc2-like kinase (Clk), among a number of other kinases, phosphorylates serine/arginine-rich proteins which play a role in alternative splicing of pre-mRNA.
- DYRK1A and DYRK1B inhibitor.
- Splicing modulator compound. Regulates alternative splicing and reduces the phosphorylation of SF2/ASF1.
- Suppresses serine/arginine-rich protein phosphorylation and affects the regulation of alternative splicing by phosphorylation of SR protein both in vitro and in vivo.
- Potential drug for Duchenne muscular dystrophy.
- The reduction of Clk2 expression in the hypothalamus by chronic pharmacological inhibition abolished the anorexigenic effect of insulin and leptin, to increase body weight, fat mass, food intake and to decrease energy expenditure in mice.
Product References
- Manipulation of alternative splicing by a newly developed inhibitor of Clks: M. Muraki, et al.; J. Biol. Chem. 279, 24246 (2004)
- Alternative splicing: a new drug target of the post-genome era: M. Hagiwara; Biochim. Biophys. Acta 1754, 324 (2005) (Review)
- Chemical treatment enhances skipping of a mutated exon in the dystrophin gene: A. Nishida, et al.; Nat. Commun. 2, 308 (2001)
- Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk): B.T. Mott, et al.; Bioorg. Med. Chem. Lett. 19, 6700 (2009)
- Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A: Y. Ogawa, et al.; Nat. Commun. 1, 86 (2010)
- Stress-responsive maturation of Clk1/4 pre-mRNAs promotes phosphorylation of SR splicing factor: K. Ninomiya, et al.; J. Cell Biol. 195, 27 (2011)
- Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II: A. Foucourt, et al.; Molecules 19, 15411 (2014)
- Deciphering targeting rules of splicing modulator compounds: case of TG003: M. Sakuma, et al.; BMC Mol. Biol. 16, 16 (2015)
- Cdc2-like kinase 2 in the hypothalamus is necessary to maintain energy homeostasis: P.G. Quaresma, et al.; Int. J. Obes. 41, 268 (2017)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
